CA2979555C - Inhibitors of hepatitis c virus polymerase - Google Patents

Inhibitors of hepatitis c virus polymerase Download PDF

Info

Publication number
CA2979555C
CA2979555C CA2979555A CA2979555A CA2979555C CA 2979555 C CA2979555 C CA 2979555C CA 2979555 A CA2979555 A CA 2979555A CA 2979555 A CA2979555 A CA 2979555A CA 2979555 C CA2979555 C CA 2979555C
Authority
CA
Canada
Prior art keywords
mmol
ethoxy
compound
hcv
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979555A
Other languages
English (en)
French (fr)
Other versions
CA2979555A1 (en
Inventor
Irina C. Jacobson
Michael D. FEESE
Sam S. Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cocrystal Pharma Inc
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of CA2979555A1 publication Critical patent/CA2979555A1/en
Application granted granted Critical
Publication of CA2979555C publication Critical patent/CA2979555C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2979555A 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase Active CA2979555C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136857P 2015-03-23 2015-03-23
US62/136,857 2015-03-23
PCT/US2016/023664 WO2016154241A1 (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Publications (2)

Publication Number Publication Date
CA2979555A1 CA2979555A1 (en) 2016-09-29
CA2979555C true CA2979555C (en) 2023-12-19

Family

ID=55759915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979555A Active CA2979555C (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Country Status (18)

Country Link
US (2) US10464914B2 (https=)
EP (1) EP3274340B1 (https=)
JP (1) JP6741747B2 (https=)
KR (1) KR20170137113A (https=)
CN (1) CN107567442B (https=)
AU (1) AU2016235246B2 (https=)
CA (1) CA2979555C (https=)
DK (1) DK3274340T3 (https=)
EA (1) EA033622B1 (https=)
ES (1) ES2748974T3 (https=)
IL (1) IL254243B (https=)
MX (1) MX379015B (https=)
NZ (1) NZ735093A (https=)
PH (1) PH12017501687A1 (https=)
PL (1) PL3274340T3 (https=)
SG (1) SG11201707527YA (https=)
TW (1) TWI731854B (https=)
WO (1) WO2016154241A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
MX2020011912A (es) * 2018-05-09 2021-01-29 Cocrystal Pharma Inc Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
CN112745216A (zh) * 2019-10-30 2021-05-04 常州锐博生物科技有限公司 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
CN116283512B (zh) * 2023-02-24 2025-04-25 博诺康源(北京)药业科技有限公司 一种合成维兰特罗及其盐的方法
WO2025111414A1 (en) * 2023-11-21 2025-05-30 Katholieke Universiteit Leuven Trpm3-modulating benzofuran derivatives
CN119350612B (zh) * 2024-12-24 2025-10-24 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ305166A (en) 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6887877B2 (en) 2001-06-11 2005-05-03 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
CN101624391A (zh) 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
EP1321463B1 (en) 2001-12-21 2007-08-08 Virochem Pharma Inc. Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
JP4926403B2 (ja) 2002-12-10 2012-05-09 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染の処置もしくは予防のための化合物および方法
AU2003291886A1 (en) 2002-12-10 2004-06-30 Virochem Pharma Inc. Thiophenederivatives for the treatment of flavivirus infections
EP1753750A1 (en) 2004-05-20 2007-02-21 Sugen, Inc. Thiophene heteroaryl amines
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
PE20070814A1 (es) 2005-12-22 2007-08-16 Smithkline Beecham Corp Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
EP2086966B1 (en) 2006-11-17 2011-09-14 GlaxoSmithKline LLC 2-carboxy thiophene derivatives as anti viral agents
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
GB0712393D0 (en) 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
EP2245023B1 (en) 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR080433A1 (es) * 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
EP2651906A4 (en) 2010-12-17 2014-06-25 Cocrystal Discovery Inc INHIBITORS OF HEPATITIS C VIRUS POLYMERASE
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑

Also Published As

Publication number Publication date
JP2018512453A (ja) 2018-05-17
EA033622B1 (ru) 2019-11-11
JP6741747B2 (ja) 2020-08-19
CA2979555A1 (en) 2016-09-29
CN107567442A (zh) 2018-01-09
KR20170137113A (ko) 2017-12-12
IL254243A0 (en) 2017-10-31
US10947210B2 (en) 2021-03-16
PL3274340T3 (pl) 2020-01-31
HK1243703A1 (zh) 2018-07-20
AU2016235246B2 (en) 2020-12-10
DK3274340T3 (da) 2019-10-07
EP3274340A1 (en) 2018-01-31
IL254243B (en) 2020-10-29
TWI731854B (zh) 2021-07-01
TW201643147A (zh) 2016-12-16
PH12017501687A1 (en) 2018-03-19
ES2748974T3 (es) 2020-03-18
US20200255393A1 (en) 2020-08-13
HK1249514A1 (en) 2018-11-02
EP3274340B1 (en) 2019-07-17
US20180050998A1 (en) 2018-02-22
US10464914B2 (en) 2019-11-05
MX379015B (es) 2025-03-10
MX2017012238A (es) 2018-02-15
AU2016235246A1 (en) 2017-09-21
BR112017020168A2 (pt) 2018-06-05
SG11201707527YA (en) 2017-10-30
NZ735093A (en) 2022-09-30
WO2016154241A1 (en) 2016-09-29
EA201792094A1 (ru) 2018-03-30
CN107567442B (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
CA2979555C (en) Inhibitors of hepatitis c virus polymerase
TWI519515B (zh) B型肝炎抗病毒劑
JP6495822B2 (ja) Hcv感染用の2’−クロロヌクレオシド類似体
JP6743135B2 (ja) 抗ウィルス性テトラヒドロフラン誘導体
US8771665B2 (en) Inhibitors of hepatitis C virus polymerase
TW201408687A (zh) 用於肝臟疾病之d-胺基酸化合物
US10426762B2 (en) Inhibitors of hepatitis C virus polymerase
JP2022544031A (ja) リシルオキシダーゼのジフルオロハロアリルアミンスルホン誘導体阻害剤、調製方法、及びそれらの使用
HK1249514B (en) Inhibitors of hepatitis c virus polymerase
BR112017020168B1 (pt) Compostos inibidores de polimerase para o vírus da hepatite c, usos dos mesmos, bem como combinação
HK1243703B (zh) C型肝炎病毒聚合酶的抑制剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210219

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250925

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251107